Cargando…

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Translational research on immune checkpoint inhibitors (ICIs) has been underway. However, in the unselected population, only a few patients benefit from ICIs. Therefore, screening predictive markers of ICI efficacy has become the current focus of attention. We collected mutation and clinical data fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Anqi, Zhang, Hongman, Meng, Hui, Deng, Ze, Gu, Tianqi, Luo, Peng, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481577/ https://www.ncbi.nlm.nih.gov/pubmed/34603277 http://dx.doi.org/10.3389/fimmu.2021.667875

Ejemplares similares

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment
por: Lin, Anqi, et al.
Publicado: (2022)

Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes
por: Yang, Qi, et al.
Publicado: (2021)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
por: Zhang, Eva, et al.
Publicado: (2021)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma
por: Liu, Rongrong, et al.
Publicado: (2022)

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
por: Lin, Anqi, et al.
Publicado: (2019)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
por: Yang, Qiao, et al.
Publicado: (2021)

Case Report: TNF-Alpha Inhibitors to Rescue Pregnancy in Women With Potential Pregnancy Loss: A Report of Ten Cases
por: Zhong, Zixing, et al.
Publicado: (2022)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022)

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer
por: Niu, Lishui, et al.
Publicado: (2022)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2023)

TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice
por: Gao, Jian, et al.
Publicado: (2022)

Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review
por: Zhang, Xu, et al.
Publicado: (2022)

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model
por: Wang, Lei, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
por: Liu, Wenhui, et al.
Publicado: (2021)

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
por: Gao, Yuan, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
por: Li, Xiaohua, et al.
Publicado: (2021)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis
por: Hu, Yue, et al.
Publicado: (2023)

Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
por: Ou, Jiayong, et al.
Publicado: (2021)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
por: Shu, Yang, et al.
Publicado: (2023)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
por: Hu, Xiangxiao, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021)

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
por: Hong, David S., et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
por: Pan, Lei, et al.
Publicado: (2023)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ik9jlogcamk3skqhaq881itjl3